David Maxwell Lyerly

This inventor holds 22 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 6 EPO patents, primarily in Infectious Disease Diagnostics. Top assignees: Techlab, Inc., Oravax, Inc., Research, Incorporated. Active years: 1985-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Maxwell Lyerly. Retrieved from https://idiyas.com/inventor/david-maxwell-lyerly

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 5)

% Patents Active = 90.9

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 1)

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 192(Granted Patents)

Location History:

Blacksburg, VA (US) (2011)
Radford, VA (US) (1985 - 2019)

Company Filing History:

Research, Incorporated

patents

4. 1 out of 825

Virginia Tech Intellectual Properties Inc.

patents

5. 1 out of 834,570

Other

patents

Years Active: 1985-2019

Loading Chart...

Areas of Expertise:

Clostridium Difficile

Biomarker

Nucleic Acid Extraction

Inflammatory Bowel Disease

Diagnostic Panel

Antibody

Toxin

Gastrointestinal Inflammation

Vaccine

Carrier State

Analyte Detection

Fecal Antibodies

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10295536 - [object Object] (2019-05-21),

2. 10295535 - Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease (2019-05-21),

3. 10196632 - Nucleic acid extraction using organic solvents to remove inhibitors (2019-02-05),

4. 9528105 - Nucleic acid extraction using organic solvents to remove inhibitors (2016-12-27),

5. 9470684 - Outer membrane protein 18 as a diagnostic marker for campylobacter (2016-10-18),

6. 9274112 - Device and method for detection of analytes (2016-03-01),

7. 9133527 - [object Object] (2015-09-15),

8. 8790880 - [object Object] (2014-07-29),

9. 8541242 - Device and method for detection of analytes (2013-09-24),

10. 8343726 - Device and method for detection of analytes (2013-01-01),

11. 7892762 - Method for diagnosing irritable bowel syndrome and monitoring inflammatory bowel disease (2011-02-22),

12. 7785818 - Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel (2010-08-31),

13. 7736858 - Method for distinguishing ulcerative colitis from Crohn's disease by detecting the presence of fecal anit-neutrophil cytoplasmic antibodies (ANCA) (2010-06-15),

14. 7560240 - Method for monitoring gastrointestinal inflammation in persons with inflammatory bowel disease(IBD) (2009-07-14),

15. 7192724 - Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker (2007-03-20),

Title: **David Maxwell Lyerly: Innovator in Biomarker Development**

Introduction

David Maxwell Lyerly, based in Radford, VA, is a prolific inventor known for his significant contributions to the medical field, specifically regarding Clostridium difficile infections. With an impressive portfolio of 22 patents, Lyerly has dedicated his career to developing innovative solutions that enhance diagnostic methods and treatment options for this challenging disease.

Latest Patents

Among his latest innovations, Lyerly's patent on "Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with Clostridium difficile disease" stands out. This groundbreaking work addresses the complex clinical presentations associated with C. difficile infections, which range from mild diarrhea to severe complications like pseudomembranous colitis and megacolon. His biomarker panel, which includes the detection of antigen (GDH), toxins A and B, and fecal lactoferrin, enables clinicians to differentiate between carrier states and active disease, significantly improving patient management and treatment efficacy.

Career Highlights

Lyerly's career is marked by his roles in influential companies such as TechLab, Inc. and Research, Incorporated. His work in these organizations has propelled advancements in understanding and managing C. difficile infections, leading to better outcomes for patients. The methods developed through his patents reflect his commitment to improving healthcare diagnostics and treatments.

Collaborations

Throughout his career, Lyerly has collaborated with notable professionals, including Tracy Dale Wilkins and James Hunter Boone. These partnerships have further enriched his research and development efforts, allowing him to combine expertise and innovate effectively in the field of infectious diseases.

Conclusion

David Maxwell Lyerly's contributions to the medical industry highlight the vital role of innovation in addressing health challenges. His patents and collaborative work with esteemed colleagues reflect his dedication to advancing the understanding and treatment of Clostridium difficile infections. As the medical community continues to evolve, Lyerly's innovations will undoubtedly pave the way for enhanced patient care and management strategies.

Profile summary based on public USPTO records.